SecurityCDXC / ChromaDex Corporation (171077407)
CEOFried Robert N
IndustryMedicinal Chemicals and Botanical Products
Institutional Owners64
Institutional Shares10,298,956 - 18.77%
Common Shares Outstanding54,866,512 shares (as of 2018-03-31)
Institutional Value$ 32,117,000 USD

Institutional Stock Ownership and Shareholders()

ChromaDex Corporation (NASDAQ:CDXC) has 64 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 10,298,956 shares. Largest shareholders include Honig Barry C, ICONIQ Capital, LLC, Vanguard Group Inc, BlackRock Fund Advisors, Tieton Capital Management, LLC, Millennium Management Llc, Goldman Sachs Group Inc, Susquehanna International Group, Llp, BlackRock Institutional Trust Company, N.A., and Geode Capital Management, Llc.
ChromaDex Corporation (NASDAQ:CDXC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 201,162 201,162 0.00 599 666 11.19
2018-05-11 13F-HR Tibra Equities Europe Ltd 76,158 320
2018-05-15 13F-HR SEGALL BRYANT & HAMILL, LLC 25,000 25,000 0.00 147 105 -28.57
2018-04-17 13F-HR MAI Capital Management 10,667 10,667 0.00 63 45 -28.57
2018-05-15 13F-HR Precept Management LLC 200,000 0 -100.00 1,176 0 -100.00
2018-04-20 13F-HR Dynasty Wealth Management, Llc 10,300 10,300 0.00 61 43 -29.51
2018-05-09 13F-HR AlphaMark Advisors, LLC 667 667 0.00 4 3 -25.00
2018-05-15 13F-HR Intellectus Partners, LLC 2,000 0 -100.00 12 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 45,100 0 -100.00 265 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 175,437 175,437 0.00 1,031 736 -28.61
2018-04-12 13F-HR Valeo Financial Advisors, Llc 500 2
2018-05-16 13F-HR Alpine Partners VI, LLC 20,680 0 -100.00 122 0 -100.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 542,994 504,525 -7.08 3,193 2,119 -33.64
2018-05-03 13F-HR Trexquant Investment LP 43,748 0 -100.00 257 0 -100.00
2018-05-08 13F-HR SIGNATUREFD, LLC 8,000 34
2018-05-11 13F-HR MML INVESTORS SERVICES, LLC 12,300 52
2018-05-11 13F-HR Quantbot Technologies LP 500 0 -100.00 2 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 0 273 0 1
2018-05-15 13F-HR National Asset Management, Inc. 14,000 59
2018-05-04 13F-HR PEDDOCK CAPITAL ADVISORS, LLC 3,380 3,380 0.00 20 14 -30.00
2018-05-15 13F-HR STATE STREET CORP 0 24,260 0 102
2018-05-09 13F-HR Cetera Advisor Networks LLC 25,000 25,000 0.00 147 105 -28.57
2018-05-14 13F-HR ICONIQ Capital, LLC 1,707,317 1,707,317 0.00 10,039 7,171 -28.57
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 8 8 0.00 47 34 -27.66
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 0 4 0 1
2018-05-11 13F-HR Cutler Group LP Call 500 7,300 1,360.00 0 1
2018-05-14 13F-HR Laurion Capital Management LP 70,667 297
2018-05-10 13F-HR Tieton Capital Management, LLC 568,400 560,720 -1.35 3,342 2,355 -29.53
2018-05-04 13F-HR Granite Investment Partners, LLC 250,276 89,316 -64.31 1,472 375 -74.52
2018-05-11 13F-HR Cutler Group LP 900 600 -33.33 5 2 -60.00
2018-05-10 13F-HR JP Morgan Chase & Co 40,109 0 -100.00 236 0 -100.00
2018-05-14 13F-HR IHT Wealth Management, LLC 1,668 1,668 0.00 10 7 -30.00
2017-10-26 13F-HR Acrospire Investment Management LLC 4,513 0 -100.00 17 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 110,729 110,729 0.00 330 367 11.21
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 25,350 0 -100.00 149 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 1,009,051 1,241,822 23.07 5,933 5,216 -12.08
2018-02-14 13F-HR GLG Partners LP 16,473 97
2018-05-15 13F-HR Jefferies Group LLC 14,000 59
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 40,001 168
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 4,668 17,368 272.07 28 73 160.71
2017-02-10 SC 13G/A Honig Barry C 8,817,832 2,409,312 -72.68
2018-05-15 13F-HR UBS Group AG 62,564 121,412 94.06 368 510 38.59
2018-05-15 13F-HR Invesco Ltd. 0 172,102 0 723
2018-05-15 13F-HR Bank of New York Mellon Corp 25,479 23,686 -7.04 150 99 -34.00
2018-05-15 13F-HR CREDIT SUISSE AG/ 16,518 0 -100.00 97 0 -100.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 252 0 -100.00 1 0 -100.00
2018-05-15 13F-HR Squarepoint Ops LLC 0 55,450 0 233
2018-05-09 13F-HR Private Advisor Group, LLC 20,750 87
2018-05-15 13F-HR DEUTSCHE BANK AG\ 22,946 56,554 146.47 134 237 76.87
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 24,798 218,039 779.26 146 916 527.40
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 0 36,860 0 155
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 11,552 11,827 2.38 68 50 -26.47
2018-05-09 13F-HR BlackRock Inc. 111,207 108,978 -2.00 654 458 -29.97
2018-05-15 13F-HR LPL Financial LLC 11,834 14,901 25.92 70 63 -10.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 14,966 229,405 1,432.84 88 964 995.45
2018-04-23 13F-HR Advisory Services Network, LLC 1,500 1,500 0.00 9 6 -33.33
2018-05-14 13F-HR Resources Investment Advisors, Inc. 4,000 4,000 0.00 24 17 -29.17
2018-05-15 13F-HR BARCLAYS PLC 102,914 64,119 -37.70 605 269 -55.54
2018-05-15 13F-HR Verition Fund Management LLC 11,416 48
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 59,340 249
2018-05-09 13F-HR NORTHERN TRUST CORP 41,605 55,902 34.36 245 235 -4.08
2018-05-04 13F-HR D.A. DAVIDSON & CO. 44,000 44,000 0.00 259 185 -28.57
2018-04-27 13F-HR Chicago Partners Investment Group LLC 15,000 15,000 0.00 88 63 -28.41
2018-05-15 13F-HR PATHSTONE FAMILY OFFICE, LLC 0 3,000 0 13
2018-05-14 13F-HR MORGAN STANLEY 16,300 115,424 608.12 96 484 404.17
2017-02-10 13F-HR BlackRock Advisors LLC 8,281 8,956 8.15 25 30 20.00
2018-04-26 13F-HR CWM, LLC 1,000 0 -100.00 6 0 -100.00
2018-04-27 13F-HR TELEMUS CAPITAL, LLC 1,700 0 -100.00 10 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 589 485 -17.66 4 2 -50.00
2018-04-13 13F-HR North Star Investment Management Corp. 153,334 108,334 -29.35 902 455 -49.56
2018-04-18 13F-HR Creative Planning 10,819 10,819 0.00 64 45 -29.69
2018-05-15 13F-HR Arete Wealth Advisors, LLC 59,259 59,259 0.00 348 249 -28.45
2018-05-11 13F-HR Cutler Group LP Put 1,200 2
2018-05-01 13F-HR OPPENHEIMER & CO INC 42,500 92,500 117.65 250 389 55.60
2018-05-15 13F-HR BlueCrest Capital Management Ltd 0 124,510 0 523
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 51,747 53,249 2.90 304 223 -26.64
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 24,668 0 -100.00 145 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 776,774 895,458 15.28 2,315 2,964 28.03
2018-04-16 13F-HR Horan Securities, Inc. 1,250 2,210 76.80 8 9 12.50
2018-05-11 13F-HR CITADEL ADVISORS LLC 59,340 249
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 0 86,600 0 364
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 0 15,200 0 64
2018-06-25 13F-HR Mount Yale Investment Advisors, Llc 68,541 288

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections. (33-0)

New Strong Sell Stocks for June 11th

2018-06-11 zacks
Accuray Incorporated (ARAY - Free Report) is a designer and seller of radiosurgery and radiation therapy systems. The Zacks Consensus Estimate for its current year earnings has been revised 52.6% downward over the last 60 days. (37-0)

What Falling Estimates & Price Mean for ChromaDex (CDXC)

2018-05-23 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. (9-0)

ChromaDex Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-11 seekingalpha
The following slide deck was published by ChromaDex Inc. in conjunction with their 2018 Q1 earnings call. (6-1)

ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's First Quarter 2018 Earnings Conference Call. My name is Daniel, and I will be the conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company's financial results for the first quarter 2018. (6-0)

CUSIP: 171077407